Online inquiry

IVTScrip™ mRNA-Anti-EGFR, GA201(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ7406MR)

This product GTTS-WQ7406MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets EGFR gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001346897.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1956
UniProt ID Q504U8
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-EGFR, GA201(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ7406MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ12789MR IVTScrip™ mRNA-Anti-NOTCH2&NOTCH3, OMP-59R5(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA OMP-59R5
GTTS-WQ2866MR IVTScrip™ mRNA-Anti-ICOS, AMG-570(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA AMG-570
GTTS-WQ4045MR IVTScrip™ mRNA-Anti-IL36RN, BI 655130(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BI 655130
GTTS-WQ3233MR IVTScrip™ mRNA-Anti-FCGRT, ARGX-113(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ARGX-113
GTTS-WQ12566MR IVTScrip™ mRNA-Anti-Felcat NGF, NV-02(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA NV-02
GTTS-WQ7619MR IVTScrip™ mRNA-Anti-TNFRSF10B, GEN1029(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA GEN1029
GTTS-WQ6021MR IVTScrip™ mRNA-Anti-IL12B, CNTO 1275(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CNTO 1275
GTTS-WQ3521MR IVTScrip™ mRNA-Anti-APP, BART(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BART
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW